Compare CVS Health Corp (CVS) vs Rivian Automotive, Inc. (RIVN) Price & Performance

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

Rivian Automotive (RIVN) trades at $16.00, up 4.03% today, with a bullish technical signal and support at $15–16. The company reported Q2 2026 EPS of -$0.47, beating estimates, and raised 2026 delivery guidance to 65,000–70,000 vehicles. Revenue grew to $5.39B in 2025, but net losses persist at -$3.65B, with cash flow negative. Analyst consensus is mixed, with a $18.70 price target and 48% buy ratings.

Outlook hinges on R2 SUV ramp-up and cost controls, with potential for margin improvement by late 2026. Key risks include high cash burn, execution delays, and EV market competition. Upside exists if profitability targets are met, but investors face volatility amid funding needs and sector headwinds.